Clinical reference Biomarker Directory
Back to directory

HAVCR1

Emerging

HAVCR1/KIM-1 is an FDA-qualified biomarker for early detection of drug-induced kidney injury, outperforming creatinine.

Also known as KIM-1 TIM-1 HAVCR1 hepatitis A virus cellular receptor 1
In plain language

This gene's protein, KIM-1, rises early after kidney tubule damage and is now an FDA-recognized way to catch drug-related kidney injury before standard tests would show a problem. Interestingly, the same gene was first discovered as the receptor hepatitis A virus uses to enter cells — a completely unrelated historical connection.

Biomarker & context

HAVCR1 encodes kidney injury molecule-1 (KIM-1), a proximal tubule cell-surface protein; the same gene was originally identified as the hepatitis A virus cellular receptor, an unrelated historical naming connection.

What it indicates

Urinary KIM-1 is an FDA/EMA-qualified biomarker for detecting drug-induced kidney injury, consistently outperforming creatinine and BUN in predicting actual kidney tissue damage in preclinical and clinical studies.

Diagnosis & clinical testing

Measured via urine immunoassay; KIM-1 is referenced in over 150 FDA drug-development regulatory submissions as a nonclinical and clinical safety biomarker, reflecting its well-established regulatory acceptance for detecting proximal tubular injury.

Guiding treatment

In drug development, rising KIM-1 during a clinical trial can signal early nephrotoxicity before creatinine changes are detectable, supporting dose adjustment or discontinuation decisions; in clinical practice, it's used alongside NGAL (discussed earlier) for early AKI detection research.

Clinical significance

Widely referenced across FDA drug development submissions; also unrelated historical namesake of the hepatitis A virus receptor.

References
  1. PMC. (2019). Kidney Injury Molecule-1: A Translational Journey.
  2. PMC. (2016). Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification.